| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbdae384a9f1ad0588422c89ddc71a00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7dfb0281008cb570feea037cd350c8f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-065 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-06 |
| filingDate |
2021-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a15cb557f03c66f7b11e5d33415d7dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0f62077e5c3b176cb240e5198f60dbb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21455b340caa0d96fdf6effbb4b81d0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41112df09de6a663b59385d434ba7024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb1c3595077f43275e5785885a75b26f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee94c5cfd9137fb766e900b1abd478a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e88cad9cf812442c2c38c00440d1b678 |
| publicationDate |
2021-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021202373-A1 |
| titleOfInvention |
A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma |
| abstract |
Described is a method for preparing an Immunoglobulin G (IgG) enriched fraction from a Cl- INH depleted plasma supernatant. Isolation of Immunoglobulin G (IgG) enriched fraction from a Cl-INH depleted plasma supernatant provided an alternative starting material for the manufacturing process. In the present invention, Cl-INH depleted plasma supernatant is treated with heparin before further processing. |
| priorityDate |
2020-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |